See updated messages from the NIDA HRP scientific leadership team.
Funding Opportunities of Note
- NIDA Avant-Garde Award Program for HIV and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-23-269
- Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) PAR-23-125
- Notice of Clarification for PAR-23-269 and PAR-23-125 - NOT-DA-24-034
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-25-024
- Notice of Change to Application Due Date for RFA-DA-22-040, "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" NOT-DA-23-041
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) RFA-DA-25-060
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
Basic Research
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed) RFA-DA-26-007
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) RFA-DA-26-008
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) RFA-DA-26-002
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) RFA-DA-26-001
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) RFA-DA-25-063
- Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-073
- Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-25-004
- Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) RFA-DA-25-005
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-009
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed) RFA-DA-25-010
- Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) RFA-DA-25-021
- Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-25-012
- Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) RFA-DA-25-013
- Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional) RFA-DA-25-022
- Single Source: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed) RFA-DA-25-015
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) RFA-DA-25-014
- NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-028
- NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-029
- Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. NOT-DA-21-030
- Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-24-001
Clinical, Epidemiological, and Implementation Science Research
- Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional). PAR-24-299
- Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional). PAR-24-300
- Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-24-298
- Notice of Participation of NIDA in RFA-MH-25-186, "Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)" NOT-DA-24-033
- Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Coordinating Center Infrastructure to Support Research on Opioid Overdose and HIV Risk in the Context of Justice Systems – NOT-DA-24-013
- Notice of Change to Application Due Date for PA-21-205, "Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)" NOT-DA-24-023
- Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances NOT-DA-25-031
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) RFA-DA-25-019
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-DA-25-059
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-DA-25-059
- Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) PA-21-205
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-023
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional) RFA-DA-23-024
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required). RFA-DA-23-008
- Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) PA-21-180
- Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) RFA-DA-24-037
Medical Consequences and Cross-Cutting Research
- Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine – NOT-DA-24-001
- Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment, NOT-DA-24-002
- Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19. NOT-DA-21-017
Program Projects and Center Grants
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional). PAR-23-064
- NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) PAR-23-076
- NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) PAR-23-049
Career Development and NRSA Fellowship Grants
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-24-089
- NIDA Training and Career Development Fellowships & Grants